Companies › Labo'Life
4 active drug programs in 6 registered trials: 6 Phase 4; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 2LHERP® Immune regulator for herpes simplex virus infections | – | Phase 4 | Herpes Simplex | Mar 2027 |
| 2LPAPI® unclear - likely immunotherapeutic agent for HPV clearance | – | Phase 4 | Human Papilloma Virus | Oct 2027 |
| 2LEBV® Unclear - composition not specified in registry text | – | Phase 4 | EBV Infection | Aug 2028 |
| 2LVERU®JUNIOR Immune regulator for HPV-related warts treatment | – | Phase 4 | Common Wart | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04065971 | 2LHERP® | Phase 4 | Herpes Simplex | Infectious disease | Mar 2027 |
| NCT04232917 | 2LPAPI® | Phase 4 | Human Papilloma Virus | Infectious disease | Oct 2027 |
| NCT04308278 | 2LEBV® | Phase 4 | EBV Infection | Infectious disease | Aug 2028 |
| NCT04308278 | 2LEBV® | Phase 4 | EBV Infection | Infectious disease | Aug 2028 |
| NCT03977753 | 2LVERU®JUNIOR | Phase 4 | Common Wart | Infectious disease | Dec 2028 |
| NCT03977753 | 2LVERU®JUNIOR | Phase 4 | Common Wart | Infectious disease | Dec 2028 |
No annotated target.
–
Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.